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Primary microcephaly (MIM 251200) is an autosomal recessive neurodevelopmental condition in which there is a
global reduction in cerebral cortex volume, to a size comparable with that of early hominids. We previously mapped
the MCPH1 locus, for primary microcephaly, to chromosome 8p23, and here we report that a gene within this
interval, encoding a BRCA1 C-terminal domain–containing protein, is mutated in MCPH1 families sharing an
ancestral 8p23 haplotype. This gene, microcephalin, is expressed in the developing cerebral cortex of the fetal
brain. Further study of this and related genes may provide important new insights into neocortical development
and evolution.
Introduction
Microcephaly is defined as a head circumference 13 stan-
dard deviations (SD) below the age-related mean. This
reduction in head size is the consequence of a small brain
(Ross and Frias 1977). Primary microcephaly (MIM
251200) is further defined by the absence of other syn-
dromic features or significant neurological deficits (other
than mild-to-moderate mental retardation). This entity
is inherited as an autosomal recessive trait and is also
known as “true microcephaly” or “microcephaly vera.”
Brain weight in primary microcephaly is markedly
reduced (typically 430 g, compared with 1,450 g in
unaffected adult males), and the cerebral cortex is dis-
proportionately small (McCreary et al. 1996). Despite
this marked reduction in size, the gyral pattern is rel-
atively well preserved, with no major abnormality in
cortical architecture (McCreary et al. 1996; Mochida
andWalsh 2001). Furthermore, the only significant neu-
rological deficit is a reduction in cognitive abilities (Bun-
dey 1992).
Brain volume in primary microcephaly is comparable
with that of early hominids (Wood and Collard 1999).
This evolutionary parallel has been of longstanding in-
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terest, leading to the proposal that primary microceph-
aly could be an atavistic disorder (Komai et al. 1955;
Mochida and Walsh 2001). Considerable expansion of
the cerebral cortex has occurred during mammalian ev-
olution, involving alterations in the timing, number, and
pattern of cell divisions during neurogenesis (Kornack
2000). Therefore, mutation of genes controlling such
processes could well underlie the pathogenesis of pri-
mary microcephaly.
Primary microcephaly is genetically heterogeneous,
with five loci currently mapped (Jackson et al. 1998;
Jamieson et al. 1999, 2000; Roberts et al. 1999; Moy-
nihan et al. 2000; Pattison et al. 2000). We defined the
first locus, MCPH1, on 8p23, by homozygosity map-
ping of consanguineous Pakistani families (Jackson et
al. 1998). In the present report, to identify the MCPH1
gene, we searched for a founder effect in linked families
and then sequenced positional candidates to identify the
causative gene.
Patients and Methods
Subjects
The two families studied have five and two affected
individuals, respectively (Jackson et al. 1998). Affected
individuals in these families (aged 6–28 years) had head
circumferences of 5–10 SD below the mean, mild-to-
moderate mental retardation, and no focal neurological
deficits or epilepsy. Linkage analysis had previously gen-
erated maximum multipoint LOD scores of 5.7 and 2.5,
respectively. The study was approved by the Leeds
Health Authority/United Leeds Teaching Hospitals Na-
tional Health Service Trust Research Ethics Committee.
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Figure 1 Schematic of the 2.1-mb MCPH1 critical region. Microsatellite markers are in boldface type. An asterisk (*) denotes flanking
markers for the ancestral haplotype. Sequenced BAC clones are shown as horizontal lines, and end-sequenced BAC clones as horizontal lines
with blackened circles at the ends. The prefix “AC” denotes a novel microsatellite marker. Marker content determined by PCR (or electronically
by BLAST) is indicated by vertical lines. NTp STS not tested against clone. The two genes in the critical region are shown, with their directions
of transcription indicated by arrows. Vertical lines indicate the positions of individual exons.
Contig Building
YAC clones were obtained from the Medical Research
Council (MRC) Human Genome Mapping Project Cen-
tre. DNA was extracted using standard techniques and
STS content determined by PCR. An in silico BAC contig
was assembled using information from the Human Ge-
nome Project Working Draft at University of California
Santa Cruz and BLAST sequence homology searches
against the genome-survey sequence, nonredundant, and
high-throughput genome-sequencing subdivisions of the
National Center for Biotechnology Information (NCBI)
sequence databases.
Genotyping
Genomic DNA was obtained from peripheral white
blood cells by standard procedures. Primer sequences for
known microsatellite markers were obtained from the
Genome Database. Novel microsatellite markers were
identified from human genome sequence in the public
databases. Novel marker names, as depicted in figure 1,
begin “ACxxx,” denoting the accession number of the
sequenced BAC they are derived from, and end “CAyy,”
indicating the sequence of the repeat and repeat number.
Fluorescently labeled primers were used to amplify
markers by PCR, which were electrophoresed on an ABI
Prism 377 and were analyzed using Genescan and Ge-
notyper (version 1.1.1) software (Applied Biosystems).
Mutation Detection
Specific primers were designed using the publicly
available genomic sequence to amplify individual exons
of microcephalin. Primer sequences are available on re-
quest. Specifically, for exon 2 the following forward and
reverse primers were used: dCTATTGGGCAGGGGAT-
GCTG and dCCAATCAGAAGACTGTCATATGAA-
TC. PCR amplification was performed using standard
procedures, and the products were screened for muta-
tions by sequencing using BigDye Terminator Cycle Se-
quencing kits (Applied Biosystems). Sequencing was per-
formed using the same primers as for PCR amplification,
and also with internal primers in the case of exon 8.
Restriction Digestion
The 74CrG mutation was confirmed using a TaqI
restriction enzyme digestion. Primers TAQ1F (dGGT-
CATCCAATGGAACAGAAAATTATC) and TAQ1R
(dGAATCAACAGCAAAATAAGTGTCTTACC) were
used to amplify part of exon 2 from genomic DNA. A
mismatch at the 3′ end of the TAQ1F primer creates a
TaqI restriction site in the PCR product amplified from
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Figure 2 Genotyping results from one affected individual and
parents from families 1 and 2, showing a region of identical alleles
shared between both families (boxed), indicative of a founder effect.
individuals with the mutation. PCR products were in-
cubated at 65C for a minimum of 3 h with TaqI and
then were separated, by electrophoresis, on a 3% aga-
rose gel (GibcoBRL).
RT-PCR of Human Fetal Tissues
The Clontech human fetal multiple tissue cDNA panel
(MTC) was used according to the manufacturer’s in-
structions. A 571-bp fragment of themicrocephalin gene
was amplified from the cDNAs by use of primers cA-F
(dGATCCCGCCGTCTGTCATGGC) and c3-R (dCTC-
CTTCATCTCTTGTAATCTCTTC). These primers are
separated by 132 kb in genomic DNA. GAPDH control
primers used were (forward) dCGACCACTTTGTCAA-
GCTC and (reverse) dCAAGGGTCTACATGGCAAC,
cDNA product size was 229 bp, and genomic product
size was ∼330 bp.
Cloning of the Mouse Microcephalin Gene
Fragments of the mouse gene were identified by trans-
lated BLAST homology searches of publicly available
mouse shotgun sequence. Primers designed from these
sequence fragments were used in RT-PCR and “leap-
frog” PCR (Gibbons et al. 1991) experiments, to clone
and confirm the entire coding sequence of the mouse
microcephalin transcript, AY070216.
In Situ Hybridization of RNA
Antisense and sense riboprobes from mouse cDNA
clones, mISH1-s and mISH1-as, containing part of the
mouse microcephalin cDNA (267–954 nt; 688 bp) in
the pCR2.1 vector (Invitrogen) with opposite orienta-
tions were labeled in in vitro transcription reactions con-
taining 35S-labeled CTP (1,250 Ci/mmol) (NEN) and T7
RNA polymerase according to the manufacturer’s pro-
tocol (Promega). Mouse embryo–section preparation
and in situ hybridization are derived from methods de-
scribed elsewhere (Cox et al. 1984).
Results
We previously reported localization of the MCPH1 pri-
mary microcephaly locus to a 13-cM interval on chro-
mosome 8p23, by analysis of consanguineous families
originating from the Mirpur region of northern Pakistan
(Jackson et al. 1998). We have since constructed a partial
yeast artificial chromosome (YAC) and an electronic BAC
contig of the region (fig. 1). A large number of known
and novel markers were mapped onto the contig and ge-
notyped in families linked to the MCPH1 locus (Jackson
et al. 1998). An ancestral haplotype of nine microsatellite
markers was thus identified (fig. 2). This refined the crit-
ical region to a 2.1-mb interval between the microsatellite
markers AC019176CA17 and D8S277. Two genes lie in
this interval, angiopoietin-2 (ANGPT2) (Grosios et al.
1999) and an uncharacterized gene, AX087870.
All exons of ANGPT2 were screened for mutations,
but no changes were found. However, whenAX087870
was screened, a CrG mutation at coding base pair 74
was found in exon 2, creating a premature stop codon
(S25X). This mutation consistently segregated with the
microcephaly phenotype in both the families sharing the
ancestral haplotype. All seven affected individuals were
homozygous for the mutation, and their eight parents,
(obligate carriers), were heterozygous for this mutation.
This sequence change was not present in 202 Pakistani
control alleles. The mutation considerably truncates the
835–amino acid (aa) AX087870 protein, whichwe have
termed “microcephalin” (fig. 3).
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Figure 3 Microcephalin structure and mutation. A, Gene organization. Scale bar represents 100 bp of exon sequence. B, Predicted domain
structure of the wild-type (WT) and mutant protein. BRCT domains are indicated by blue boxes. The position of the S25X mutation is indicated
by an arrow. C, Nonsense mutation in exon 2 in affected individual from family 1.
Figure 4 Expression pattern of microcephalin; RT-PCR analysis
of human fetal tissues. Upper panel, a 570-bpmicrocephalin fragment
amplified by use of primers from exons 1 and 6, to include the entire
first BRCT domain. Lower panel, GAPDH control.
Microcephalin is predicted to contain three BRCA1
C-terminal (BRCT) domains, with the S25X mutation
occurring in the first of these motifs. These domains
interact to form homo/hetero BRCTmultimers (Huyton
et al. 2000). Interactions also occur with other proteins
and directly with DNA at double-strand breaks. Se-
quence database searches identify several human pro-
teins with homology, based primarily on the C-terminal
paired BRCT domains. They include the BRCA1protein
itself, a DNA topoisomerase II–binding protein, and a
cloned transcript (BAA13389) with homology to Schi-
zosaccharomyces pombe rad4/cut5.
RT-PCR of human fetal tissues confirms that micro-
cephalin is expressed in fetal brain (fig. 4). A similar
level of expression is also present in fetal liver and kid-
ney, and transcripts are detectable at low levels in a
range of other fetal tissues (fig. 4), as well as in a number
of adult tissues (data not shown).
The mouse ortholog of microcephalin was next
cloned using RT-PCR. This protein contains 822 amino
acids and has only 57% identity to the human protein
(fig. 5). The most conserved regions are the BRCT do-
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Figure 5 ClustalX alignment of human and mouse microcephalin proteins. Identical amino acids shaded in black, conservative substitutions
in gray. BRCT domains (as predicted by SMART) are boxed.
mains, where there is 80% identity. The mouse gene
maps to chromosome 8A2, a region that also contains
the Angpt2 gene and shows conserved synteny with hu-
man 8p23.
In situ hybridization experiments on fetal mouse sec-
tions confirm that microcephalin is expressed during
neurogenesis. In fetal brain, high levels of gene expres-
sion localize to the developing forebrain (fig. 6) and, in
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Figure 6 Expression ofmicrocephalinmRNA in the fetal mouse
brain. A, B, and C Expression ofmicrocephalinmRNA in 7-mm E13.5
fetal mouse sagittal brain sections. Antisensemicrocephalin riboprobe
(A), toluidine blue counterstained section (B), sense microcephalin ri-
boprobe (C). lv p lateral ventricle; s p corpus striatum; d p dien-
cephalon; mv p mesencephalic vesicle.
particular, to the walls of the lateral ventricles. In this
region, progenitor cells divide to produce neurons that
migrate to form the cerebral cortex (Angevine and Sid-
man 1961). Hence, the expression pattern of microce-
phalin in the brain is consistent with a role in neuro-
genesis and in regulation of the size of the cerebral
cortex.
Discussion
We report here the first demonstration of a molecular
defect underlying primary microcephaly. We have iden-
tified an ancestral haplotype shared by two MCPH1
families, and we show that affected individuals in both
families are homozygous for a truncating mutation of a
novel gene, microcephalin. This gene encodes a BRCA1
C-terminal (BRCT) domain–containing protein of as-
yet-undefined function. In situ hybridization demon-
strates that microcephalin is expressed in particular
around the lateral ventricles of the developing forebrain,
suggesting that the gene has a role in regulating the size
of the cerebral cortex. The gene is also expressed in other
regions of the brain, at lower levels, as well as in other
tissues. Expression at sites other than those in which the
phenotype manifests is frequently seen in genes causing
developmental disorders (e.g., Dixon et al. 1997; Shah-
bazian et al. 2002). A variety of factors may account
for restriction of phenotype to specific tissues in different
conditions, and the way that mutation of microcephalin
causes a reduction of brain size, in the apparent absence
of other phenotypic effects, will require further
investigation.
BRCT domains are known to be present in several
key proteins controlling the cell cycle (Huyton et al.
2000). Therefore, mutation inmicrocephalinmay cause
primary microcephaly by perturbing normal cell-cycle
regulation in neural progenitors. The length of the cell-
cycle and duration of neurogenesis are crucial in deter-
mining total cortical cell number, and such parameters
have significantly altered during evolution from rodents
to primates (Kornack 2000). However, other factors
may also be involved in pathogenesis of primary mi-
crocephaly. Neural cell number is also dependent on the
number of founder cells at the start of neurogenesis, the
relative proportions of asymmetric and symmetric cell
division, and the extent of cell death (Kornack 2000).
In particular, BRCT domains are found in many DNA-
repair proteins (Huyton et al. 2000), and loss of func-
tion of DNA-repair genes can lead to excessive apop-
totic cell death during neurogenesis (Mochida and
Walsh 2001). In this respect, it is interesting to note that
nibrin, the protein mutated in Nijmegen breakage syn-
drome, also contains a BRCT domain (Varon et al.
1998). Nijmegen breakage syndrome manifests as mi-
crocephaly, in combination with growth retardation,
immunodeficiency, chromosome instability, and a
marked predisposition to malignancy (International
Nijmegen Breakage Syndrome Study Group 2000).
Identification of themicrocephalin gene will facilitate
the clinical discrimination of genetic from nongenetic
disorders involving microcephaly and may aid the iden-
tification of the pathway(s) mutated in the other forms
of autosomal recessive primary microcephaly, MCPH2-
5 (Mochida and Walsh 2001). Identification of further
mutations alongside functional characterization of mi-
crocephalin will be useful to confirm its role in the path-
ogenesis of microcephaly. Functional studies of micro-
cephalin should provide insights into the regulation of
cortical neural cell number, potentially aiding under-
standing of neural progenitor/stem cell regulation and
evolution of the cerebral cortex.
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